About Us

Ernexa Therapeutics is a preclinical stage company developing off-the-shelf, synthetic, induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (iMSC) therapies. To our knowledge, Ernexa stands apart as the only company in the U.S. currently developing iMSCs, engineered to express proinflammatory cytokines to treat cancer. Ernexa’s allogeneic iMSC platform leverages the intrinsic “tumor homing” ability of MSCs, functioning as a Trojan horse to safely and effectively enhance anti-tumor immune responses through selective delivery of immunostimulatory agents to the tumor microenvironment (TME) and potential to convert immunologically ‘cold’ tumor to ‘hot’. Our lead product candidate, ERNA-101, expresses an IL-7_IL-15 fusion cytokine. The company’s initial focus is to develop ERNA-101 in platinum resistant ovarian cancer (PROC). The company is also investigating ERNA-201, anti-inflammatory cytokine (IL-10)-secreting iMSCs in inflammatory/auto-immune disorders like rheumatoid arthritis.

Vision

At Ernexa, our vision is to improve the lives of patients with difficult-to-treat diseases through innovative, effective, safe, and accessible synthetic induced mesenchymal stem cell (iMSC) therapies

Mission

Ernexa's mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable, off-the-shelf cell therapies that restore hope